AbCellera Biologics Inc. Common Shares (ABCL) is a publicly traded Healthcare sector company. As of July 7, 2026, ABCL trades at $7.69 with a market cap of $2.40B and a P/E ratio of -15.99. ABCL moved -2.03% today. Year to date, ABCL is +128.12%; over the trailing twelve months it is +107.11%. Its 52-week range spans $1.89 to $8.42. Analyst consensus is strong buy with an average price target of $9.40. Rallies surfaces ABCL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
AbCellera Appoints Biotech Veteran Dr. Lynn Seely to Board of Directors: AbCellera has appointed Dr. Lynn Seely to its board of directors, effective July 2026, expanding its governance team with her biotech leadership. Dr. Seely brings over two decades of drug development and strategic planning experience from senior executive and investment roles.
| Metric | Value |
|---|---|
| Price | $7.69 |
| Market Cap | $2.40B |
| P/E Ratio | -15.99 |
| EPS | $-0.48 |
| Dividend Yield | 0.00% |
| 52-Week High | $8.42 |
| 52-Week Low | $1.89 |
| Volume | 7.77M |
| Avg Volume | 0 |
| Revenue (TTM) | $79.21M |
| Net Income | $-143.96M |
| Gross Margin | 0.00% |
6 analysts cover ABCL: 0 strong buy, 6 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $9.40.